Amoy Diagnostics Co.,Ltd. (China)

Amoy Diagnostics Co., Ltd. is a biotechnology and pharmaceutical company located in Xiamen. It was founded in 2008 by Professor Zheng Limou, a nationally appointed expert. The company specializes in precision molecular diagnostics for cancer and is committed to providing compliant and high-quality diagnostic products and services to benefit patients. Amoy Diagnostics has various qualifications and certifications, including a national enterprise technology center, a postdoctoral research workstation, a gene testing technology application demonstration center authorized by the National Development and Reform Commission, and the status of a national high-tech enterprise. Their GMP standard factory has obtained certifications from the National Medical Products Administration (NMPA) and the European Union ISO13485. The company possesses core technologies such as ADx-ARMS®, Super-ARMS®, ddCapture®, and ADx-HANDLE®, which have been authorized in China, the United States, the European Union, and Japan. These technologies have received recognition, including the National Science and Technology Progress Award (second prize) and the China Patent Award (silver prize). Amoy Diagnostics' products cover various major cancers that have the conditions for precision medicine. Some of their products have no competitors in the market. In addition to being widely used in domestic tertiary hospitals, some products have been approved for market entry and inclusion in local medical insurance in Japan and South Korea, setting a precedent for overseas approval of companion diagnostics for tumors in China. The company also operates the Xiamen Amoy Medical Laboratory and the Shanghai Xiawei Medical Laboratory, which hold medical institution practice licenses and are certified by the College of American Pathologists (CAP). They specialize in third-party clinical inspection services. Amoy Diagnostics' products and services are chosen by customers in dozens of countries and regions worldwide. Hundreds of thousands of cancer patients benefit from their products each year, effectively avoiding the misuse and abuse of tumor drugs. The company aims to be at the forefront of industry innovation and empower clinical development of original drugs through companion diagnostics. It has established strategic partnerships with top domestic and international pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Weigao, Hengrui, and BeiGene, to build the future of precision medicine in oncology.